1. Home
  2. IQI vs PCRX Comparison

IQI vs PCRX Comparison

Compare IQI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IQI
  • PCRX
  • Stock Information
  • Founded
  • IQI 1992
  • PCRX 2006
  • Country
  • IQI United States
  • PCRX United States
  • Employees
  • IQI N/A
  • PCRX N/A
  • Industry
  • IQI Finance Companies
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IQI Finance
  • PCRX Health Care
  • Exchange
  • IQI Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • IQI 524.6M
  • PCRX 1.2B
  • IPO Year
  • IQI N/A
  • PCRX 2011
  • Fundamental
  • Price
  • IQI $10.04
  • PCRX $25.44
  • Analyst Decision
  • IQI
  • PCRX Buy
  • Analyst Count
  • IQI 0
  • PCRX 9
  • Target Price
  • IQI N/A
  • PCRX $26.22
  • AVG Volume (30 Days)
  • IQI 162.1K
  • PCRX 853.8K
  • Earning Date
  • IQI 01-01-0001
  • PCRX 02-27-2025
  • Dividend Yield
  • IQI 4.61%
  • PCRX N/A
  • EPS Growth
  • IQI N/A
  • PCRX N/A
  • EPS
  • IQI N/A
  • PCRX N/A
  • Revenue
  • IQI N/A
  • PCRX $694,957,000.00
  • Revenue This Year
  • IQI N/A
  • PCRX $5.55
  • Revenue Next Year
  • IQI N/A
  • PCRX $5.64
  • P/E Ratio
  • IQI N/A
  • PCRX N/A
  • Revenue Growth
  • IQI N/A
  • PCRX 4.40
  • 52 Week Low
  • IQI $8.05
  • PCRX $11.16
  • 52 Week High
  • IQI $10.00
  • PCRX $31.67
  • Technical
  • Relative Strength Index (RSI)
  • IQI 59.64
  • PCRX 56.91
  • Support Level
  • IQI $9.82
  • PCRX $25.37
  • Resistance Level
  • IQI $10.09
  • PCRX $27.36
  • Average True Range (ATR)
  • IQI 0.08
  • PCRX 1.35
  • MACD
  • IQI 0.01
  • PCRX -0.21
  • Stochastic Oscillator
  • IQI 84.52
  • PCRX 19.48

About IQI Invesco Quality Municipal Income Trust

Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Share on Social Networks: